UPB

Upstream Bio, Inc. Common Stock
UPB
Market cap $482M

8.98 USD

+0.20

2.28%

At close Apr 29, 4:00 PM EDT

After hours

8.98

+0.00

0.00%

1 day

2.28%

5 days

-13.40%

1 month

46.73%

3 months

-12.39%

6 months

-64.31%

Year to date

-44.91%

1 year

-59.18%

5 years

-59.18%

10 years

-59.18%

About: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

74.69% more ownership

Funds ownership: 0% [Q3] → 74.69% (+74.69%) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for UPB.

See Analyst Rankings

Financial journalist opinion

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Verekitug's less frequent dosing and good safety profile offer potential advantages, but its success hinges on upcoming Phase 2 data readouts.

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

3 Dividend Giants To Buy As Tariffs Hit Stocks

This year's tariff storms have hit tech stocks, semiconductor stocks and even metal and mining stocks. Now, they're starting to hit dividend stocks, too.

3 Dividend Giants To Buy As Tariffs Hit Stocks

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio to Present at Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MA Tuesday, March 4, 2025, 11:50 a.m.

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027.

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio Announces Addition to Russell 2000® Index

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.

Upstream Bio Announces Addition to Russell 2000® Index

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the closing of its upsized initial public offering of 17,250,000 shares of its common stock at a public offering price of $17.00 per share, which includes 2,250,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock.

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

See News Rankings

Charts implemented using Lightweight Charts™